Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2023-12-29 Director's Dealing
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Exercise of options and PDMR dealing
Director's Dealing Classification · 1% confidence The document is an official notification of a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically a Non-Executive Director (John Johnston) exercising options and selling shares. The text explicitly includes the standard PDMR disclosure table required by regulatory bodies. This falls directly under the 'Director's Dealing' category.
2023-12-29 English
FORM 4 SUBMISSION
Director's Dealing
2023-12-28 English
CEO Transition and Revenue Guidance Update
Regulatory Filings Classification · 1% confidence The document is a press release issued via RNS (Regulatory News Service) announcing a CEO transition (Maher Masoud succeeding Doug Doerfler) and providing an update on 2023 revenue guidance. While it contains management information, the primary purpose of this specific filing is to announce a change in senior management. According to the filing definitions, 'MANG' is the appropriate category for announcements of changes in the board of directors or senior management.
2023-12-12 English
8-K
Regulatory Filings
2023-12-11 English
Exercise of options and PDMR dealing
Director's Dealing Classification · 1% confidence The document is an official notification of share transactions by a Person Discharging Managerial Responsibilities (PDMR), specifically the CEO of MaxCyte, Inc. It details the exercise of stock options and the subsequent sale of those shares. This falls directly under the definition of 'Director's Dealing' (Code: DIRS), which covers reports of personal share transactions by company directors and executives.
2023-12-07 English
FORM 4 SUBMISSION
Director's Dealing
2023-12-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.